Join our scientific experts online for our upcoming 'Fireside Q&A' webinar, "Reach the Clinic Faster: Integrated Biopharmaceutics & Drug Substance Strategies" on July 27th
Drug developers face many challenges and considerations in the preclinical and candidate development stage. They start with selecting the right molecule to take forward into clinical development and understanding the best drug substance and drug product development strategy to reach the clinic. To simplify and expedite this phase, developers can leverage an integrated biopharmaceutics, drug substance and drug product development strategy in order to make science-led, data driven decisions that greatly improve formulation performance and streamline the outsourcing process. The tight integration of these key activities under a single organization improves the supply chain by removing them from the critical path, and allows for a seamlessly transition into clinical research with 'clinic ready' deliverables.
Join scientific experts from Quotient Sciences in drug substance, biopharmaceutics, and candidate development for a Q&A panel discussion on July 27th to learn more about the benefits of integrating biopharmaceutics and drug substance activities in order the accelerate timelines to first-in-human studies, minimize risks and improve the likelihood of downstream success. Our panelists include our Head of Drug Substance Operations, Dr Richard Castledine, Principal Research Fellow for Candidate Development, Dr Steve Byard, and Executive Director, Candidate Development, Dr Eleanor Row.
July 27th - 10am PST / 1pm EST / 6pm BST